Charles River Laboratories | CRL - Equity Capital And Reserves



Charles River Laboratories reported $3.31B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Agilent USD 6.37B 234M Jul/2025
Align Technology USD 3.79B 57.74M Mar/2025
Bio-Rad Laboratories USD 7.13B 449.3M Jun/2025
Bruker USD 1.87B 33.9M Jun/2025
Cardinal Health USD -2781000000 167M Jun/2025
Charles River Laboratories USD 3.31B 119.03M Jun/2025
Cigna USD 40.43B 204M Jun/2025
CVS Health USD 77.55B 622M Jun/2025
Danaher USD 52.33B 1.48B Jun/2025
Dentsply International USD 1.96B 50M Jun/2025
Elevance Health USD 43.85B 1.35B Jun/2025
Galapagos EUR 2.64B 104.07M Jun/2025
Hologic USD 4.84B 223.8M Jun/2025
Humana USD 18.3B 544M Jun/2025
Illumina USD 2.26B 110M Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
IQVIA Holdings USD 5.78B 199M Jun/2025
Laboratory Of America USD 8.47B 151M Jun/2025
Lonza CHF 9.33B 23M Dec/2024
McKesson USD -1967000000 107M Jun/2025
Merck EUR 28.26B 1.64B Jun/2025
Mettler Toledo International USD -258793000 76.81M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Quest Diagnostics USD 7.23B 299M Jun/2025
Revvity USD 7.64B 29.74M Mar/2025
Thermo Fisher Scientific USD 49.36B 227M Mar/2025
United Therapeutics USD 7.17B 366.4M Jun/2025
UnitedHealth USD 100.81B 8.15B Mar/2025
Waters USD 2.16B 197.42M Jun/2025
West Pharmaceutical Services USD 2.93B 246M Jun/2025